Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study

@inproceedings{Yamaue2015RandomizedPI,
  title={Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study},
  author={Hiroki Yamaue and Takuya Tsunoda and Masaji Tani and Motoki Miyazawa and Kenji Yamao and Nobumasa Mizuno and Takuji Okusaka and Hideki Ueno and Narikazu Boku and Akira Fukutomi and Hiroshi Ishii and Shinichi Ohkawa and Masayuki Furukawa and Hiroyuki Maguchi and Masafumi Ikeda and Yosuke Togashi and Kazuto Nishio and Yasuo Ohashi},
  booktitle={Cancer science},
  year={2015}
}
Gemcitabine is a key drug for the treatment of pancreatic cancer; however, with its limitation in clinical benefits, the development of another potent therapeutic is necessary. Vascular endothelial growth factor receptor 2 is an essential target for tumor angiogenesis, and we have conducted a phase I clinical trial using gemcitabine and vascular endothelial growth factor receptor 2 peptide (elpamotide). Based on the promising results of this phase I trial, a multicenter, randomized, placebo… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 69 references

Cancer statistics

  • JD Berlin, P Catalano, JP Thomas, JW Kugler, DG Haller, AB Benson
  • CA Cancer J Clin
  • 2013

assay for diagnosis of EML4-ALK-positive non-small cell lung cancer

  • S Asahara, K Takeda, K Yamao, H Maguchi, H. Yamaue
  • J Thorac Oncol 2012;
  • 2012

Similar Papers

Loading similar papers…